MGC beefs up epilepsy expertise
Published 13-JUL-2016 16:40 P.M.
|
2 minute read
Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.
In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.
The below articles were written under our previous business model. We have kept these articles online here for your reference.
Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.
Click Here to View Latest Articles
MGC Pharmaceutical (ASX:MXC) has added intellectual weight to its fight against severe epilepsy as it ramps up stakeholder engagement with a focus on medical cannabis’ role in combating the disease.
It told its shareholders this morning that Israeli-bases Dr Uri Kramer has joined the company as a member of its strategic advisory board – which will guide the company on establishing clinical trials using medical cannabis in the treatment of severe epilepsy.
Dr Kramer is a highly regarded expert in the field of paediatric neurology and paediatric epilepsy — and he’ll join Australian cardiologist Dr Ross Walker on the design of trials and product development.
MXC has focused its pharmaceutical efforts on treating epilepsy, entering into a research agreement with SipNose back in March, with the agreement around the development of a cannabinol (CBD)-based treatment to be delivered through the Sipnose device.
The pair have set up in the Hadassah Medical Centre in Israel – but the signing of Dr Kramer further demonstrates its pharmaceutical intent.
MXC also has a line of CBD-based cosmetic products in the market which helps deliver underlying revenue to the company.
These include facial creams, eye serums, soaps, toners, and cleansing milks with compounds derived from medical cannabis.
On the lobbying front
MXC has stepped up its lobbying effort in Australia in an effort to allow the company to conduct clinical trials and ultimately have something of a first-mover advantage in the country.
It has previously teamed up with the University of Sydney to study the market potential of the Australian medical cannabis market – with a white paper finding that it was a $150 million opportunity.
A series of both state and federal moves on the relaxation of restrictive regulations around medical cannabis has opened the doors for medical cannabis players such as MXC to potential make a market entry.
It should be noted that regulations are not set in stone and are able to be changed – investors should seek independent advice before deciding whether or not to invest.
The appointment of Dr Kramer will help establish its credentials in the Australian market and elsewhere as a market-leader in the use of medical cannabis to treat epilepsy.
MXC said that it had started the stakeholder engagement process, including talks with state and federal governments, medical professionals, academics, and other industry participants.
General Information Only
This material has been prepared by Jason Price. Jason Price is an authorised representative (AR 000296877) of 62 Consulting Pty Limited (ABN 88 664 809 303) (AFSL 548573) (62C), and a Director of S3 Consortium Pty Ltd (trading as StocksDigital).
This material is general advice only and is not an offer for the purchase or sale of any financial product or service. The material is not intended to provide you with personal financial or tax advice and does not take into account your personal objectives, financial situation or needs. Although we believe that the material is correct, no warranty of accuracy, reliability or completeness is given, except for liability under statute which cannot be excluded. Please note that past performance may not be indicative of future performance and that no guarantee of performance, the return of capital or a particular rate of return is given by 62C, Jason Price, StocksDigital, any of their related body corporates or any other person. To the maximum extent possible, 62C, Jason Price, StocksDigital, their related body corporates or any other person do not accept any liability for any statement in this material.
Conflicts of Interest Notice
S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.
Publication Notice and Disclaimer
The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.
Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.
This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.
